The challenge in comparing pharmaceutical pricing systems lies in their structural differences. The US model is built on multiple layers of rebates, discounts and incentives, while single-payer systems rely on centralised negotiations and confidential agreements.
The mirage of US pharmaceutical pricing and how it could obscure the impact of 'MFN'
October 22, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Proteomics International secures WA Government grant to advance world-first blood test for endometriosis
November 9, 2025 - - Australian Biotech -
AVITA Medical narrows losses and secures EU approval as reimbursement challenges ease
November 9, 2025 - - Australian Biotech -
From potential to practice - AI Health Summit to focus on adoption, implementation and governance
November 9, 2025 - - Latest News -
Call for national action to lift immunisation rates as whooping cough spread worsens
November 9, 2025 - - Latest News -
Pharmacy Guild - 'You can’t fragment care you’re not receiving'
November 8, 2025 - - Latest News -
The 'Dispatched' Week in Review' Podcast - 7 November
November 7, 2025 - - Podcast -
Donald Trump announces 'MFN' deals with Lilly and Novo Nordisk and end to 'global freeloading'
November 7, 2025 - - Latest News
